13:32:37 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-08-15 Kvartalsrapport 2024-Q2
2024-05-16 Ordinarie utdelning SENZA 0.00 SEK
2024-05-15 Årsstämma 2024
2024-02-14 Bokslutskommuniké 2023
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-05 Ordinarie utdelning SENZA 0.00 SEK
2023-05-04 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-06 Ordinarie utdelning SENZA 0.00 SEK
2022-05-05 Årsstämma 2022
2022-02-11 Bokslutskommuniké 2021
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-06 Ordinarie utdelning SENZA 0.00 SEK
2021-05-05 Årsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-11 Ordinarie utdelning SENZA 0.00 SEK
2020-05-08 Årsstämma 2020
2020-02-13 Bokslutskommuniké 2019
2019-12-18 Extra Bolagsstämma 2019
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-16 Ordinarie utdelning SENZA 0.00 SEK
2019-05-15 Årsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-09 Ordinarie utdelning SENZA 0.00 SEK
2018-05-08 Årsstämma 2018
2018-02-14 Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Senzagen är verksamt inom medicinteknik. Bolaget utvecklar och genomför genomiska in vitro-tester, vilket innebär att olika kemikaliers toxikologiska förmåga inte testas på djur utan istället i provrör. Bolaget har utvecklat en teknologisk plattform som används för att studera substansers påverkan producerat av aktörer inom läkemedel, kosmetika- och kemikalieindustrin. Forskning och utveckling sker från huvudkontoret i Lund.
2021-01-22 08:30:00

SenzaGen has renewed and expanded its global collaboration agreement with the contract research organization Charles River Laboratories, one of the world's leading companies in laboratory services. To meet the growing interest in risk assessment of chemicals by using SenzaGen's non-animal test platform GARD®, the collaboration was broadened to now include all tests in the GARD portfolio.

Charles River Laboratories International, Inc. is a leading global contract research organization offering preclinical laboratory services to the pharmaceutical, chemical, agrochemical and medical device industries, among others. Companies in these industries are increasingly looking for alternative test methods that are more precise and cost-effective in the long run. The collaboration with SenzaGen was initiated in 2017.

“We are very pleased with our continued and expanded collaboration with Charles River Laboratories and to work with them to drive the change in establishing alternative testing methods widely. The collaboration is in line with our commercial strategy to form a global partner network and Charles River Laboratories is a leading service provider to the industries we prioritize, giving us a very strong sales channel. The fact that Charles River Laboratories continue to offer GARD to their customers and include our latest developed tests confirms the strength of our technology,” says Axel Sjöblad, CEO of SenzaGen.

“At Charles River we are passionate about our role in improving the quality of people´s lives and we strive at providing the best scientific solutions. We are happy to continue our collaboration with SenzaGen to offer the state-of-the-art GARD technology for sensitization assessments. Since 2017, our customers have been requesting GARD sensitization services and appreciate its unique ability to provide potency classification according to CLP, among other features”, says Walter Westerink, Section Head Flexible Innovation Team, Charles River Laboratories.